New Therapy Options in Advanced Small Cell Lung Cancer (SCLC) Webinar

These videos are intended for healthcare professionals for informative purposes only. Click on the video above to watch the complete webinar.

 

SCLC Webinar Chapters

Dr Paul Mitchell

2:31 to 3:03                 Introduction: Dr Paul Mitchell

3:24 to 5:33                 Background: Small Cell Lung Cancer

5.34 to 9.07                 IMpower 133: Atezolizumab + Carboplatin + etoposide in 1L ES-SCLC

9:08 to 10:50              CASPIAN Trial: Durvalumab +Tremilimumab + etoposide in ES-SCLC

10:51 to 11:25            ECOG-ACRIN EA5161 – Cisplatin/carboplatin + etoposide + nivolumab in ES-SCLC

11:26 to 12:20            Keynote- 606. Pembrolizumab + etoposide +Cisplatin/Carboplatin in stage IV SCLC

12:21 to 12:55            Summary ES-SCLC: Key first-line IO trials

12:56 to 13:25            Checkmate 451 – Maintenance strategy of Immunotherapy

13:26 to 13:55            Biomarkers (PD-L1 AND TMB)

13.56 to 15.27            ES-SCLC: Adding Thoracic Radiotherapy and TROG Phase 2 study

15:28 to 16:17            Limited Stage small cell lung cancer (LS-SCLC)

16:18 to 17:15            Second line options and beyond

17:16 to 18:19            Summary of 1^st line therapies in SCLC

18:20 to 21:41:           Zepzelca Access Program Analysis (SCLC)

 

Dr Santiago Ponce-Aix

22:05 to 23:04            Introduction for Dr Ponce-Aix

23:31 to 24:37            New Standard of Care for ES-SCLC

24.38 to 26.28:           Retreatment with Platinum as 2^nd line (>90 days)

26:29 to 29:29            Immunotherapy in 2^nd line

29:30 to 34:26            Biomarker Selection

34:27 to 36:49            Lurbinectedin Basket Trial Data

36:50 to 37:23            ATLANTIS Trial

37:24 to 39:05            RESILIENT Trial

39:06 to 41:28            Lurbinectedin plus Irinotecan

41.29 to 44.33            Lurbinectedin plus Atezolizumab

44:34 to 45:32            Summary

 

Dr Amit Jain

46:00 to 46:34            Introduction – Dr Amit Jain

46:39 to 47:46            Paradigms in Treatment of Extensive SCLC

47:47 to 49:49            SCLC – A Challenging Disease

49:50 to 51:47            Chemotherapy in 1^st and 2^nd Line

51:48 to 52:33            Use of Immunotherapy in 1^st Line

52:35 to 53:05            Use of Immunotherapy as Maintenance and in 2nd Line

53:07 to 54:01            NCCN Guidelines

54:02 to 55:30            Lurbinectedin – Key Points

55:31 to 57:14            Treatments on the Horizon

57:15 to 59:28            Case Study

 

Panel discussion

59:59 to 1:00:57         Q1: Does the 3-year OS data from CASPIAN influence the long-term efficacy perception of IO + chemo in 1L ES-SCLC patients?

1:00:58 to 1:06:53      Q2 (Dr Tanujaa): Why is it that unlike the non-small cell lung cancer patients our small cell lung cancer patients don’t seem to respond as well to immune checkpoint inhibitors? Any idea?

1:06:56 to 1:08:16      Q3: Why do you think Atlantis trial failed?

1:08:17 to 1:10:05      Q4: In your practice what do you use as second line treatment for the platinum refractory patients? Do you use a single agent lurbinectedin or do you do the combination of lurbinectedin plus Irinotecan?

1:10:06 to 1:11:06      Q5:  Is lurbinectedin approved in Singapore?

1:11.07 to 1:12:17      Q6. Is the current trial with lurbinectedin plus atezolizumab (first line maintenance) enough for USA full approval of lurbinectedin in second line of SCLC? Or will it be necessary to launch a new phase 3 trial with lurbinectedin to get the full approval?

1:12:18 to 1:15:06      Q7: Thanks, Dr Santiago it’s wonderful hearing your insights as you are in the thick of it and you’re planning new trials?  What are you going to put your money on if you want your phase III, 2^nd line trial? What’s your combination of choice there’s so many ways to do this now?  So, if you had to pick one, which one would it be?

1:15:07 to 1:15:56      Q8: You mentioned about PD-L1 in small cell lung cancer, do you routinely test for that in your patients?

1:15:58 to 1:16:39      Q9: Do you routinely re-biopsy your patients who progress on first line or second line therapy?

1:16:40 to 01:18:45    Q10: How important is maintenance immunotherapy in first line SCLC?

01:18:46 to 1:20:53    Q11 (Dr Tanujaa): For example, if you have an extensive stage small cell lung cancer patient and had just had etoposide plus carboplatin as first-line therapy and they progress without any immune checkpoint inhibitor or a similar situation where limited stage lung cancer had concurrent chemo RT and progress within three months and haven’t seen immune checkpoint inhibitors and they are platinum refractory.  So, what will be your choice for second line therapy? Would you consider using immune checkpoint inhibitors in the second line or would you still go back to your standard second line chemotherapy options?

1:20:55 to 1:22:25      Q12: Why temozolomide for your case study? And why not other chemotherapy agents?

1:22:26 to 1:24:55      Q13: What do you think of drugs to treat CNS metastasis in the future? What will be the brain penetration of the newer drugs?

01:24:58 to 01:25:30  Q14: Do you have any data on the CNS activity of lurbinectedin?

01:25:31 to 1:27:10    Q15: Do you often offer local therapy after response to etoposide platinum plus immune checkpoint inhibitors? What do you think about the role of local radiotherapy in this case?

01:27:14 to 01:28:33  Q16: What is the most promising biomarker in SCLC according to you?

1:28:33 to 1:31:07      Q17: Let’s say if we were having this webinar five years down the road, do you think we will be still talking about overall survival being about what slightly more than a year or do you see things changing tremendously? What are your views?

 

ZEPZELCA^® is a registered trademark of PharmaMar SA. ZEPZELCA^® is under license from PharmaMar SA.